MovDisordV3, Main, Exploration, bibRecord, 001963

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

Identifieur interne : 001963 ( Main/Exploration ); précédent : 001962; suivant : 001964

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

Auteurs : Maria Nord [Suède] ; Peter Zsigmond [Suède] ; Anita Kullman [Suède] ; Kerstin Rstrand [Suède] ; Nil Dizdar [Suède]

Source :

Movement Disorders [ 0885-3185 ] ; 2010-02-15.

RBID : ISTEX:7411BA85636A057E85FC2CC3CEACEEBF41C3190F

Descripteurs français

Pascal (Inist)
- Inhibiteur enzyme, Liquide céphalorachidien, Lévodopa, Maladie de Parkinson, Pathologie du système nerveux.

English descriptors

KwdEn :
- Administration, Oral, Aged, Aged, 80 and over, Antiparkinson Agents (blood), Antiparkinson Agents (cerebrospinal fluid), Antiparkinson Agents (therapeutic use), Area Under Curve, COMT, Catechols (administration & dosage), Cerebrospinal fluid, Dose-Response Relationship, Drug, Enzyme Inhibitors (administration & dosage), Enzyme inhibitor, Female, Humans, Levodopa, Levodopa (blood), Levodopa (cerebrospinal fluid), Levodopa (therapeutic use), Male, Mepivacaine (administration & dosage), Microdialysis (methods), Middle Aged, Nervous system diseases, Nitriles (administration & dosage), Parkinson Disease (blood), Parkinson Disease (cerebrospinal fluid), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's Disease, Time Factors, continuous infusion, levodopa.
MESH :
- chemical , administration & dosage : Catechols, Enzyme Inhibitors, Mepivacaine, Nitriles.
- chemical , blood : Antiparkinson Agents, Levodopa.
- chemical , cerebrospinal fluid : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- blood : Parkinson Disease.
- cerebrospinal fluid : Parkinson Disease.
- drug therapy : Parkinson Disease.
- methods : Microdialysis.
- Administration, Oral, Aged, Aged, 80 and over, Area Under Curve, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Time Factors.

Abstract

Levodopa combined with a dopa‐decarboxylase inhibitor, such as carbidopa, shifts the metabolism to the COMT pathway. Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations. We studied the effects of the enzyme inhibitors entacapone and carbidopa on the levodopa concentrations in CSF and in blood. Five PD patients with wearing‐off underwent lumbar drainage and intravenous microdialysis. Samples were taken 12 h daily for 3 days. Day 1; intravenous levodopa was given, day 2; additional oral entacapone 200 mg tid, day 3; additional oral entacapone 200 mg tid and carbidopa 25 mg bid. Levodopa in CSF and in dialysates was analysed. The AUC for levodopa increased both in blood and CSF when additional entacapone was given alone and in combination with carbidopa. The Cmax of levodopa in both CSF and blood increased significantly. Additional entacapone to levodopa therapy gives an increase of Cmax in CSF and in blood. The increase is more evident when entacapone is combined with carbidopa. © 2010 Movement Disorder Society

Url:

https://api.istex.fr/document/7411BA85636A057E85FC2CC3CEACEEBF41C3190F/fulltext/pdf

DOI: 10.1002/mds.22613

Affiliations:

Suède

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF</title>
<author><name sortKey="Nord, Maria" sort="Nord, Maria" uniqKey="Nord M" first="Maria" last="Nord">Maria Nord</name>
</author>
<author><name sortKey="Zsigmond, Peter" sort="Zsigmond, Peter" uniqKey="Zsigmond P" first="Peter" last="Zsigmond">Peter Zsigmond</name>
</author>
<author><name sortKey="Kullman, Anita" sort="Kullman, Anita" uniqKey="Kullman A" first="Anita" last="Kullman">Anita Kullman</name>
</author>
<author><name sortKey=" Rstrand, Kerstin" sort=" Rstrand, Kerstin" uniqKey=" Rstrand K" first="Kerstin" last=" Rstrand">Kerstin  Rstrand</name>
</author>
<author><name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7411BA85636A057E85FC2CC3CEACEEBF41C3190F</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22613</idno>
<idno type="url">https://api.istex.fr/document/7411BA85636A057E85FC2CC3CEACEEBF41C3190F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002899</idno>
<idno type="wicri:Area/Istex/Curation">002899</idno>
<idno type="wicri:Area/Istex/Checkpoint">000642</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Nord M:the:effect:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20077469</idno>
<idno type="wicri:Area/PubMed/Corpus">001A27</idno>
<idno type="wicri:Area/PubMed/Curation">001A27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001569</idno>
<idno type="wicri:Area/Ncbi/Merge">002975</idno>
<idno type="wicri:Area/Ncbi/Curation">002975</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002975</idno>
<idno type="wicri:Area/Main/Merge">001D99</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0161576</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C31</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002088</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000801</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Nord M:the:effect:of</idno>
<idno type="wicri:Area/Main/Merge">002388</idno>
<idno type="wicri:Area/Main/Curation">001963</idno>
<idno type="wicri:Area/Main/Exploration">001963</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF</title>
<author><name sortKey="Nord, Maria" sort="Nord, Maria" uniqKey="Nord M" first="Maria" last="Nord">Maria Nord</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Neurology, University Hospital, Linköping</wicri:regionArea>
<wicri:noRegion>Linköping</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zsigmond, Peter" sort="Zsigmond, Peter" uniqKey="Zsigmond P" first="Peter" last="Zsigmond">Peter Zsigmond</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Neurosurgery, University Hospital, Linköping</wicri:regionArea>
<wicri:noRegion>Linköping</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kullman, Anita" sort="Kullman, Anita" uniqKey="Kullman A" first="Anita" last="Kullman">Anita Kullman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Chemistry, University Hospital, Linköping</wicri:regionArea>
<wicri:noRegion>Linköping</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey=" Rstrand, Kerstin" sort=" Rstrand, Kerstin" uniqKey=" Rstrand K" first="Kerstin" last=" Rstrand">Kerstin  Rstrand</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Chemistry, University Hospital, Linköping</wicri:regionArea>
<wicri:noRegion>Linköping</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Neurology, University Hospital, Linköping</wicri:regionArea>
<wicri:noRegion>Linköping</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Chemistry, University Hospital, Linköping</wicri:regionArea>
<wicri:noRegion>Linköping</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-02-15">2010-02-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="363">363</biblScope>
<biblScope unit="page" to="367">367</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">7411BA85636A057E85FC2CC3CEACEEBF41C3190F</idno>
<idno type="DOI">10.1002/mds.22613</idno>
<idno type="ArticleID">MDS22613</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (blood)</term>
<term>Antiparkinson Agents (cerebrospinal fluid)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Area Under Curve</term>
<term>COMT</term>
<term>Catechols (administration & dosage)</term>
<term>Cerebrospinal fluid</term>
<term>Dose-Response Relationship, Drug</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Enzyme inhibitor</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (blood)</term>
<term>Levodopa (cerebrospinal fluid)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Mepivacaine (administration & dosage)</term>
<term>Microdialysis (methods)</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Nitriles (administration & dosage)</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (cerebrospinal fluid)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's Disease</term>
<term>Time Factors</term>
<term>continuous infusion</term>
<term>levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Catechols</term>
<term>Enzyme Inhibitors</term>
<term>Mepivacaine</term>
<term>Nitriles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Microdialysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Area Under Curve</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Inhibiteur enzyme</term>
<term>Liquide céphalorachidien</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa combined with a dopa‐decarboxylase inhibitor, such as carbidopa, shifts the metabolism to the COMT pathway. Adding the peripheral acting COMT inhibitor entacapone provides improvement for patients with PD suffering from motor fluctuations. We studied the effects of the enzyme inhibitors entacapone and carbidopa on the levodopa concentrations in CSF and in blood. Five PD patients with wearing‐off underwent lumbar drainage and intravenous microdialysis. Samples were taken 12 h daily for 3 days. Day 1; intravenous levodopa was given, day 2; additional oral entacapone 200 mg tid, day 3; additional oral entacapone 200 mg tid and carbidopa 25 mg bid. Levodopa in CSF and in dialysates was analysed. The AUC for levodopa increased both in blood and CSF when additional entacapone was given alone and in combination with carbidopa. The Cmax of levodopa in both CSF and blood increased significantly. Additional entacapone to levodopa therapy gives an increase of Cmax in CSF and in blood. The increase is more evident when entacapone is combined with carbidopa. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Suède</li>
</country>
</list>
<tree><country name="Suède"><noRegion><name sortKey="Nord, Maria" sort="Nord, Maria" uniqKey="Nord M" first="Maria" last="Nord">Maria Nord</name>
</noRegion>
<name sortKey=" Rstrand, Kerstin" sort=" Rstrand, Kerstin" uniqKey=" Rstrand K" first="Kerstin" last=" Rstrand">Kerstin  Rstrand</name>
<name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name>
<name sortKey="Dizdar, Nil" sort="Dizdar, Nil" uniqKey="Dizdar N" first="Nil" last="Dizdar">Nil Dizdar</name>
<name sortKey="Kullman, Anita" sort="Kullman, Anita" uniqKey="Kullman A" first="Anita" last="Kullman">Anita Kullman</name>
<name sortKey="Zsigmond, Peter" sort="Zsigmond, Peter" uniqKey="Zsigmond P" first="Peter" last="Zsigmond">Peter Zsigmond</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001963 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001963 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:7411BA85636A057E85FC2CC3CEACEEBF41C3190F
   |texte=   The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.